Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guselkumab for treating moderately to severely active Crohn's disease [ID6238]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guselkumab for treating moderately to severely active ulcerative colitis TS ID 10713Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC